Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.39 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.39 |
| ▸ | IGF1R | P08069 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6829386 | 0.82 | NR3C2 (0.39) | AOC3KDM4E | |
| SCHEMBL3746491 | 0.80 | RIPK1 (0.55) | AOC3KDM4E | |
| SCHEMBL8027464 | 0.80 | RIPK1 (0.55) | AOC3KDM4E | |
| SCHEMBL6831554 | 0.78 | AOC3 (0.57) | AOC3IGF1R | |
| SCHEMBL31489960 | 0.78 | AOC3 (0.48) | AOC3KDM4EHTTGABBR2GABBR1 | |
| SCHEMBL9296581 | 0.77 | AOC3 (0.45) | AOC3KDM4EHTTGABBR2GABBR1 | |
| SCHEMBL684740 | 0.75 | AOC3 (0.40) | AOC3HTTGABBR2GABBR1 | |
| SCHEMBL12167826 | 0.75 | AOC3 (0.40) | AOC3HTT | |
| SCHEMBL22623869 | 0.73 | RIPK1 (0.67) | AOC3KDM4EMEN1KMT2A | |
| SCHEMBL10458397 | 0.73 | AOC3 (0.45) | AOC3KDM4EHTTGABBR2GABBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004043921-A1 | NOVEL PROCESS FOR THE PREPARATION OF 4-ARYL-3-HYDROXYMETHYL-1-METHYLPIPERIDINES. | NATCO PHARMA LIMITED (IN) | 2004-05-27 | — | — | WO | disclosed |